Table 1. Comparison of the clinical characteristics of the study population at baseline.
| Variables | Overall | Without Mutations | With Mutations | P value |
|---|---|---|---|---|
| (n = 44) | (n = 28) | (n = 16) | ||
| Age, mean (SD), years | 52.5 (12.3) | 54.1 (11.8) | 49.8 (12.9) | 0.26 |
| Male sex, n (%) | 32 (72.7) | 22 (78.6) | 10 (62.5) | 0.30 |
| Type of transplant, n (%) | 0.24 | |||
| Kidney | 19 (43.2) | 13 (46.4) | 6 (37.5) | 0.57 |
| Liver | 9 (20.5) | 6 (21.4) | 3 (18.8) | >0·99 |
| Heart | 8 (18.2) | 5 (17.9) | 3 (18.8) | >0.99 |
| Lung | 5 (11.4) | 1 (3.6) | 4 (25.0) | 0.050 |
| Kidney-pancreas | 3 (6.8) | 3 (10.7) | 0 (0) | 0.29 |
| CMV serostatus, n (%)a | 0.21 | |||
| D+/R- | 26 (61.9) | 14 (53.8) | 12 (75.0) | 0.17 |
| D+/R+ | 13 (31.0) | 10 (38.5) | 3 (18.8) | 0.30 |
| D-/R+ | 2 (4.8) | 2 (7.7) | 0 (0) | 0.52 |
| D-/R- | 1 (2.4) | 0 (0) | 1 (6.3) | 0.38 |
| Induction therapy, n (%) | ||||
| Basiliximab | 21 (47.7) | 16 (57.1) | 5 (31.3) | 0.098 |
| Antithymocyte globulin | 10 (22.7) | 7 (25.0) | 3 (18.8) | 0.72 |
| Initial maintenance therapy, n (%)b | ||||
| Mycophenolate mofetil | 36 (81.8) | 23 (82.1) | 13 (81.3) | >0.99 |
| Tacrolimus | 35 (79.5) | 24 (85.7) | 11 (68.8) | 0.25 |
| Steroids | 34 (77.3) | 21 (75.0) | 13 (81.3) | 0.72 |
| Cyclosporine | 6 (13.6) | 2 (7.1) | 4 (25.0) | 0.17 |
| mTOR inhibitors | 5 (11.4) | 2 (7.1) | 3 (18.8) | 0.34 |
| CMV prophylaxis, n (%) | 24 (54.5) | 12 (42.9) | 12 (75.0) | 0.039 |
| ≤3 monthsc | 18 (75.0) | 10 (83.3) | 8 (66.7) | 0.64 |
| ≥6 monthsc | 6 (25.0) | 2 (16.7) | 4 (33.3) |
Abbreviations: D-, negative donor; D+, positive donor; R-, negative recipient; R+, positive recipient; mTOR, mammalian target of rapamycin; n, number of cases; SD, standard deviation
a CMV serostatus not specified in 2 patients
b May have had more than 1 initial maintenance
c Percentages calculated for patients with CMV prophylaxis